A potent platelet aggregation inducer, aggretin, was purified from Malayan-pit-viper (Calloselasma rhodostoma) venom by ionic-exchange chromatography, gel-filtration chromatography and HPLC. It is a heterodimeric protein (29 kDa) devoid of esterase, phospholipase A and thrombin-like activity. Aggretin (> 5 nM) elicited platelet aggregation with a lag period in both human platelet-rich plasma and washed platelet suspension.
INTRODUCTION
Platelets are essential for the normal haemostasis. When blood vessels get injured, platelets adhere to exposed subendothelial matrix, collagen and von Willebrand factor. This adhesion results in platelet activation, release of biologically active substances (e.g. ADP and thromboxane A2), followed by platelet aggregation, forming a haemostatic plug [1] . A variety of physiological inducers are able to activate platelets, including collagen, ADP, thromboxane A2, adrenaline (epinephrine) and thrombin. There are two intracellular pathways in mediating platelet activation by most inducers [2] . Upon stimulation, Ptdlns (4, 5) P3 is cleaved by phospholipase C to form Ins(1,4,5)P3 (InsP3) and diacylglycerol. InsP2 releases Ca2+ from the intracellular stores and rises the cytosolic free Ca2+ level [3] , while diacylglycerol activates protein kinase C, leading to protein phosphorylation, granule secretion and fibrinogen-receptor expression [4] . Thromboxane A2 formation is the landmark of the second pathway. This pathway operates when arachidonate is released from membrane phospholipids either by the direct action of phospholipase A2 or by the sequential action of phospholipase C and diacylglycerol lipase [5, 6] . Through a cascade of enzyme-mediated transformation, the liberated arachidonate is then metabolized to prostaglandin endoperoxides and thromboxane A2, which are potent inducers in activating platelets. It is also well recognized that the release of ADP from platelets accounts for, at least in part, the did not significantly affect its aggregating activity. Aggretin caused a significant increase of [3H]InsP formation in [3H]Insloaded platelets, intracellular Ca2+ mobilization and thromboxane B2 formation. Neomycin, a phospholipase C inhibitor, completely inhibited both the increase of [3H]InsP and intracellular Ca2+ mobilization of platelets stimulated by aggretin. A monoclonal antibody (6F1) directed against glycoprotein Ia/Ila inhibited platelet shape change and aggregation induced by aggretin.'25I-aggretin bound to platelets with a high affinity (Kd = 4.0 + 1.1 nM), and the number of binding sites was estimated to be 2119 + 203 per platelet. It is concluded that aggretin may act as a glycoprotein Ia/Ila agonist to elicit platelet aggregation through the activation ofendogenous phospholipase C, leading to hydrolysis of phosphoinositides and subsequent intracellular Ca2+ mobilization. activation of platelets by collagen, especially at low concentrations [7] .
Snake-venom components affect platelet function in various ways. Some venom proteins induce release reaction and platelet aggregation, while others inhibit these reactions [8] . The most pronounced anti-platelet constituents are Arg-Gly-Asp (RGD)-containing trigramin-like peptides, which have been identified as specific fibrinogen receptor [i.e. glycoprotein (GP) Ilb/Illa complex] antagonists [8] and have been termed 'disintegrins' [9] . Several non-coagulant, non-enzymic principles that cause platelet aggregation have been purified from different snake venoms [10] [11] [12] [13] [14] [15] [16] [17] . However, the detailed action mechanisms of these platelet-aggregation inducers are still obscure. Recently a plateletaggregation inducer (trimucytin) from Trimeresurus mucrosquamatus (Taiwan habu snake) venom was shown to be a collagen-like activator. It might activate platelets through the binding of a collagen-like receptor on the platelet membrane. A monoclonal antibody directed against GPIa inhibited platelet aggregation caused by collagen and trimucytin [18] .
Thrombocytopenia is a common syndrome after Calloselasma rhodostoma (Malayan pit viper) has bitten [19] , and the crude venom possessed a potent platelet-activating activity in washed rabbit platelet suspensions [10] . In the present study we purified the platelet-activating component (aggretin) from this snake venom and investigated its mechanism of action in activating human platelets. Thromboxane B2 assay At 6 min after the addition of platelet-aggregation inducer, 2 mM EDTA and 50 ,M indomethacin were added to halt thromboxane formation. After centrifugation in an Eppendorf microcentrifuge (model 5415C) for 2 min, thromboxane B2 the supernatant was assayed by an EIA kit (Cayman Chemical Co.).
Measurement of the intracellular Ca2+ level
The concentration of cytosolic free Ca21 was determined using a fluorescent probe, Fura-2, according to the method of Pollock and Rink [25] . In brief, Fura-2/AM (1 ,uM) was incubated with ACD-anticoagulated platelet-rich plasma at 37°C for 50 min. Then Fura-2/AM-loaded platelet suspension was prepared similarly to the preparation of the platelet suspension mentioned above. The intracellular Ca2+ level was measured by the fluorescence change monitored by a Hitachi fluorescence spectrophotometer (excitation at 339 nm, emission at 500 nm). The intracellular Ca2+ concentration was calculated by using the equation given by Grynkiewicz et al. [26] . To see whether the influx of extracellular Ca2+ contributes the cytosolic Ca2+ increase, isolated human platelets were suspended in Ca2+-free Tyrode solution after the last wash and these experiments were carried out simultaneously with those under normal conditions.
Measurement of the production of [H]InsP
After the centrifugation of ACD-anticoagulated PRP at 1500 g at 37°C for 10 min, the platelet pellets were resuspended in 1 ml of Ca2+-free and BSA-free Tyrode solution containing 75 #uCi/ml of myo-[2-3H]Ins (Amersham International) and 1 mM EDTA. After incubation at 37°C for 2 h, the platelets were collected by centrifugation and suspended in normal Tyrode solution mentioned above. Phosphoinositide breakdown was initiated by adding aggregation inducer to 1 ml ofplatelet suspension (3 x 108 platelets/ml) with stirring at 900 rev./min and 37°C for 6 min. Indomethacin (50 ,M) was added in order to rule out the possible contribution of endogenous thromboxane-induced phosphoinositide hydrolysis. An equal volume of 10% (w/v) trichloroacetic acid was added to stop the reaction. After centrifugation at 2000 g for 10 min, 1 ml of supernatant was pooled and trichloroacetic acid was removed by extraction with three 5 ml portions of diethyl ether. The aqueous phase containing the inositol phosphates was adjusted to pH 7-8 and diluted to 4 ml with distilled water before application to a Dowex-1 ion-exchange column for separation of the inositol phosphates as described by Neylon and Summers [27] . All the experiments were performed in the presence of 5 mM LiCl to inhibit InsP phosphatase. Because the levels of InsP2 and InsP3 were very low, we measured InsP as an index of the total inositol phosphates formed.
Radlolabelling of aggretin
The purified aggretin was labelled with Na125I (Amersham Intternational) using Enzymobeads (Bio-Rad) at room temperature for 25 min, and the labelled aggretin was separated from free 3 .0 x 101 platelets/ml. Binding of 151-aggretin to platelets
Ligand-platelet binding studies were performed at room temperature (25°C) by a previously described method [28] . In brief, the incubation mixture (total volume 500 ,tl; 3 x 108 platelets/ml) was composed of 400 1l of platelet suspension (3.75 x 108/ml), 10 
Effects of some inhibitors on aggretin-induced platelet aggregation
In order to determine the contribution of endogenous thromboxane in aggretin-induced platelet activation, we examined the effect of indomethacin, an inhibitor of cyclo-oxygenase. Indomethacin (50 ,uM), which inhibited collagen (10 ,ug/ml)-induced human platelet aggregation completely (results not shown), only partially attenuated the aggregation induced by aggretin (1.0 /tg/ml) ( Table 1) . The ADP scavengers, apyrase (1 unit/ml) and CP/CPK (5 mM, 5 units/ml), had no effect on aggretininduced aggregation (Table 1 ). Tosylarginine methyl ester (100 ,uM) blocked the aggregation of washed platelets induced by thrombin (0.2 units/ml), while it did not affect aggretin (1 ,g/ml)-induced aggregation ( Figure 3 Effects of 6F1 (monoclonal antibody against GPIa/lla) and RGD-containing peptides (rhodostomin and GRGDS) on aggretin-Induced platelet aggregatlon and ATP release 6F1 (50 ,ug/ml) and RGD-containing peptides, rhodostomin (1 jug/ml) and GRGDS (200 ,g/ml), were incubated with human platelets for 3 min prior to the addition of aggretin (1 #g/ml). After the addition of aggretin, platelet aggregation (upward tracing; AT= change in light transmission) and ATP release (downward tracing) were continuously recorded for 6 min. Platelet aggregation and ATP release reaction were monitored by the turbidimetric method and by bioluminence changes respectively. Table 1 Effects of some antiplatelet agents on the aggregation of washed human platelets Induced by aggretn Platelets were pretreated with indomethacin (50 ,uM), neomycin (4 mM), mepacrine (50 ,uM), TMB-8 (100 1M), PGE1 (1 #M), EDTA (5 mM) for 3 min or tosylarginine methyl ester (TAME) (100 ,uM), apyrase (1 unit/ml), CP/CPK (5 mM/5 units/ml) for 1 min, then aggretin (1 ,tg/ml) was added to trigger platelet aggregation. formation caused by aggretin (1 jug/ml) (82% inhibition), whereas it only slightly blocked aggregation induced by aggretin (23 % inhibition) ( Table 1 ).
Ca2+ mobilization By using the specific Ca2+ probe Fura-2, we further investigated the mechanisms involved in aggretin-induced platelet activation and aggregation. Aggretin (1 /sg/ml) caused an increase (from 75 + 2 to 298 + 20 nM, n = 3) in intracellular Ca2+ in platelets with a lag period (Figure 4 ). Even in Ca2+-free medium, aggretin showed an equal ability to elevate the level of intracellular Ca2+ (results not shown). This enhanced Ca2+ flux was completely inhibited by neomycin (4 mM). However, indomethacin (50 ,uM)
did not affect the increase in the level of intracellular Ca2+ caused by aggretin (Figure 4) . Pretreatment of the RGD-containing peptides rhodostomin and GRGDS partially inhibited (by 50 %) the aggretin-induced cytosolic Ca2+ increase (results not shown).
Phosphoinositide breakdown
Many aggregation inducers trigger phosphoinositide breakdown, which subsequently leads to platelet activation and aggregation [31] [32] [33] . Table 2) .
Effects of monoclonal antibodies and RGD-contalning peptides on platelet aggregation and the release reactlon caused by aggretin
To analyse the possible receptor of aggretin on the platelet membrane, the effect of some monoclonal antibodies (6F1, AP-1, 7E3 and 6D1) were tested. At 10 jug/ml, the monoclonal antibody (6F 1) raised against GPIa/IIa, which has been proposed to be a collagen receptor [34, 35] , dramatically inhibited collageninduced platelet shape-change (reflected by the initial decrease in transmission) and aggregation [36] . Similarly, 6F1 also blocked the platelet shape-change, aggregation and release reaction induced by Aggretin (Figure 3 ) without exerting any inhibitory effect on those elicited by other inducers (e.g. thrombin) (T. F. Huang and C. Z. Liu, unpublished work). However, a higher concentration (50 ,g/ml) of 6F1 was required in order to block the platelet aggregation and ATP release completely (Figure 3) . By contrast, other monoclonal antibodies (AP-1 and 6D1, raised against platelet GPIb) prolonged human thrombin (0.2 unit/ml)-induced platelet aggregation without exerting any appreciable effect on platelet aggregation induced by aggretin (T. interfering with the shape-change and release reaction elicited by several aggregation agonists [20] , including aggretin ( Figure 3 ).
Binding of aggretin to human platelets
As shown in Figure 5 reaction [32] . Aggretin induced platelet aggregation, ATP release (Figures 2 and 3 ) and thromboxane formation. It also.enhanced the total InsP formation ( Table 2 ) and cytosolic Ca2+ level ( Figure 4 ). Platelet aggregation and the increase in cytosolic Ca2+ caused by aggretin were not significantly blocked by indomethacin (Table 1 and Fig. 4 [20] . They also inhibited human platelet aggregation, but not the shape-change and release reaction elicited by aggretin (Figure 3 ), even though they attenuated (50 % inhibition) the cytosolic Ca2+ increase in platelets (results not shown). This indicates that the binding of fibrinogen to GPIIb-IIIa and the subsequent platelet aggregation is not essential for the initial activation ofplatelets triggered by aggretin, but platelet aggregation may potentiate the increase in cytosolic
Ca2+
GPIa/IIa has been demonstrated to be a candidate for the collagen receptor [34, 35] , because monoclonal antibody (6F1), raised against GPIa/IIa, specifically inhibited platelet shapechange and aggregation induced by collagen [36] . Since 6F1 blocked t-he platelet shape-change and aggregation elicited by aggretin, and the number of GPIa/IIa molecules (2000/platelet) expressed on platelets (401 is similar to the number of binding sites (2119/platelet) of aggretin, GPIa/IIa is essential, and might be the functional receptor for aggretin to activate platelets. Although GPIa/IIa expressed on platelet membrane is important for both collagen and aggretin to induce platelet aggregation, there is still some diversity. As shown in Figure 2 , aggretin induced human platelet aggregation in an all-or-none manner, which was characterized by a longer latent period required to initiate shapechange and the subsequent aggregation when a lower dose of aggretin was added. Unlike aggretin, collagen dose-dependently induced platelet aggregation with an identical latent period in causing shape-change (T. F. Huang and C. Z. Liu, unpublished work). Indomethacin (50 ,uM), which completely inhibited collagen (10 ,ug/ml)-induced platelet aggregation, only partially attenuated the platelet aggregation induced by aggretin (Table  1) , even though thromboxane formation was almost abolished. In addition, the ADP scavenger CP/CPK, which inhibited collagen (5 ,ug/ml)-induced platelet aggregation remarkably, had no significant effect on the aggregation triggered by aggretin (0.2-1.0 ,ug/ml) (results not shown).
Trimucytin, a collagen-like inducer purified from T. mucrosquamatus venom, activates rabbit platelets through phosphoinositide breakdown and Ca2+ mobilization independent of ADP release and thromboxane formation [14] . Although signal transduction in platelet activation and aggregation evoked by trimucytin is similar to that of aggretin, pretreatment of trimucytin did not displace the binding of aggretin to human platelets (T. F. Huang and C. Z. Liu, unpublished work). It suggests that trimucytin and aggretin may bind to different epitopes of GPIa or GPIIa.
All these data obtained in the present study suggest that aggretin might bind to a collagen-like receptor (either Ia or Ila) with a high affinity (Kd = 4.0±1.1 nM) in a bivalent-cationindependent manner and then activate human platelets through the activation of endogenous phospholipase C, leading to InP,3 formation and intracellular Ca2+ mobilization, and, subsequently, platelet aggregation. Aggretin may become an useful probe for the detection of membrane GPIa or GPIIa and for the elucidation of signal-transduction pathways involved with platelet GPIa or GPIIa.
